340
Participants
Start Date
August 6, 2015
Primary Completion Date
February 28, 2020
Study Completion Date
August 12, 2025
AZD9150
AZD9150
MEDI4736
MEDI4736
AZD5069
AZD5069
tremelimumab (treme)
tremelimumab
Research Site, Brussels
Research Site, Brussels
Research Site, Dresden
Research Site, Antwerp
Research Site, Edegem
Research Site, Namur
Research Site, Berlin
Research Site, Milan
Research Site, Hamburg
Research Site, Fairfax
Research Site, Madrid
Research Site, Madrid
Research Site, Hanover
Research Site, Plantation
Research Site, Sarasota
Research Site, Birmingham
Research Site, Toledo
Research Site, Lafayette
Research Site, Detroit
Research Site, Cologne
Research Site, Billings
Research Site, Frankfurt
Research Site, Houston
Research Site, Denver
Research Site, München
Research Site, Los Angeles
Research Site, Los Angeles
Research Site, Duarte
Research Site, La Jolla
Research Site, San Francisco
Research Site, Seattle
Research Site, Orange
Research Site, Boston
Research Site, Morristown
Research Site, Cincinnati
Research Site, Jena
Research Site, Barcelona
Research Site, Hospitalet deLlobregat
Research Site, Birmingham
Research Site, London
Research Site, London
Research Site, Manchester
Research Site, Surrey
Research Site, Taunton
Lead Sponsor
Collaborators (1)
MedImmune LLC
INDUSTRY
AstraZeneca
INDUSTRY